Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + Temozolomide in Newly Diagnosed Glioblastoma
NCT07047066Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of fluzoparib in glioblastoma (GBM), sponsored by Tongji Hospital. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
fluzoparib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07047066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07047066.